Response rate
| . | Overall (N = 48) . | Prior anti-CD38∗ (n = 14) . | Prior pom† (n = 16) . | Prior carfilzomib (n = 14) . | 1 prior line (n = 19) . | ≥2 prior lines (n = 29) . | High-risk FISH (n = 12) . |
|---|---|---|---|---|---|---|---|
| CR | 3 (6.3%) | 0 | 0 | 0 | 3 (15.8%) | 0 | 0 |
| VGPR | 9 (18.8%) | 2 (14.3%) | 0 | 2 (14.3%) | 5 (26.3%) | 4 (14%) | 2 |
| PR | 15 (31.3%) | 3 (21.4%) | 5 (31.2%) | 4 (28.6) | 6 (31.6%) | 9 (31%) | 20 |
| SD | 19 (39.6%) | 8 (57.1%) | 9 (56.3%) | 7 (50%) | 5 (26.3%) | 14 (48%) | 9 |
| ORR (95% CI) | 56.3% (42.3-69.3) | 35.7% (16.3-61.3) | 31.3% (14.2-55.6) | 42.9% (21.4-67.4) | 73.7% (51.2-88.2) | 44.8% (28.4-62.3) | 16.7% (4.7-44.8) |
| Not evaluable | 2 (4.2%) | 1 (7.1%) | 2 (12.5%) | 1 (7.1%) | 0 | 2 | 1 |
| . | Overall (N = 48) . | Prior anti-CD38∗ (n = 14) . | Prior pom† (n = 16) . | Prior carfilzomib (n = 14) . | 1 prior line (n = 19) . | ≥2 prior lines (n = 29) . | High-risk FISH (n = 12) . |
|---|---|---|---|---|---|---|---|
| CR | 3 (6.3%) | 0 | 0 | 0 | 3 (15.8%) | 0 | 0 |
| VGPR | 9 (18.8%) | 2 (14.3%) | 0 | 2 (14.3%) | 5 (26.3%) | 4 (14%) | 2 |
| PR | 15 (31.3%) | 3 (21.4%) | 5 (31.2%) | 4 (28.6) | 6 (31.6%) | 9 (31%) | 20 |
| SD | 19 (39.6%) | 8 (57.1%) | 9 (56.3%) | 7 (50%) | 5 (26.3%) | 14 (48%) | 9 |
| ORR (95% CI) | 56.3% (42.3-69.3) | 35.7% (16.3-61.3) | 31.3% (14.2-55.6) | 42.9% (21.4-67.4) | 73.7% (51.2-88.2) | 44.8% (28.4-62.3) | 16.7% (4.7-44.8) |
| Not evaluable | 2 (4.2%) | 1 (7.1%) | 2 (12.5%) | 1 (7.1%) | 0 | 2 | 1 |
CR, complete response; FISH, fluorescence in situ hybridization; PR, partial response; SD, stable disease; VGPR, very good partial response.
Response rate for 7 patients with anti-CD38 antibody as last prior line: 28.6% (1 VGPR and 1 PR).
Response rate for 6 patients with pomalidomide as last prior line: 33% (2 PR). Of the 6 patients, 2 were treated with daratumumab or isatuximab, in which SD was the best response.